Sanofi : FDA Approves Enjaymo, First Treatment For Use In Patients With Cold Agglutinin Disease
5/2 17:51
(RTTNews) - Sanofi (SNYNF, SNY) said that the U.S. Food and Drug Administration has approved Enjaymo (sutimlimab-jome) to decrease the need for red blood cell transfusion due to hemolysis in adults with cold agglutinin disease or CAD....